retatrutide phase 2 trial type 2 diabetes weight loss 2024 The MariTide of once-monthly maridebart cafraglutide, a peptide–antibody conjugate, showed substantial reduction in participants with obesity with or without diabetes. Full trial results and Research Summary Retatrutide: A Triple Agonist Shaping
Description
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study
in particular, it has been reported that only 3% of GLP-1 positive cells express GPR40, and 23% GPR120 (266)
GLP-1 Receptor Agonists and the Risk of Fragility Fractures in Older Adults with Type 2 Diabetes
Compounded versions may contain different excipients, and their milk transfer properties have not been specifically studied
Our ISPOR poster aimed to address this gap
00967-0/asset/e600c3fc-c7b2-4bc5-adb8-0138decc3ad3/main.assets/gr3_lrg.jpg)
[DOI] [PubMed] [Google Scholar] 76.Akella A, Deshpande SB
